Trial Profile

A Single-arm, multicenter, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Tucidinostat (Primary)
Indications Clear cell sarcoma; Dermatofibrosarcoma; Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
Focus Therapeutic Use

Most Recent Events

25 Dec 2023 Planned number of patients changed from 53 to 74.
06 Jun 2023 Preliminary results (n=46) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
11 Apr 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com